Singapore, Aug. 5 -- Body Vision Medical, a leader in artificial intelligence (AI)-powered intraoperative imaging, has announcde that its LungVision advanced imaging platform has received Pre-Market Approval fromSingapore'sHealth Sciences Authority (HSA).

This clearance enables full commercialisation of LungVision inSingaporeand represents a significant milestone in the company's ongoing mission to improve early and accurate diagnosis of lung cancer worldwide.

Lung cancer is a significant health concern inSingapore, ranking as the second most common cancer in men and the third most common in women. Over a five-year period (2018-2022), approximately 9,000 cases were diagnosed. According to the Singapore Cancer Registry, most patients are...